Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status unconfirmed · Phase 1
Conditions studied: Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas
In brief
The purpose of this study is to determine the safety, tolerability, and the maximum tolerated dose/recommended phase II dose of carboxyamidotriazole orotate (CTO) as a single agent in patients with advanced or metastatic solid tumors; in combination with oral Temodar® in patients with glioblastoma or other recurrent malignant gliomas; or in combination with oral Temodar® and radiation therapy in patients with newly diagnosed glioblastoma or other malignant gliomas.
Key facts
- Study ID
- NCT01107522
- Run by
- Tactical Therapeutics, Inc.
- People needed
- 100
- Starts
- 2010-05-01
- Expected to finish
- 2026-01-01
- Last updated by the study team
- 2025-09-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- New York University — New York, New York, United States
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
- Providence Cancer Center — Portland, Oregon, United States
- Oregon Health and Sciences University — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.